Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Curr Treat Options Oncol. 2014 Jun;15(2):187–209. doi: 10.1007/s11864-014-0285-5

Table 4. Promising therapeutic agents for HCL [114, 116, 118, 120, 125].

Agent Mechanism of action
Vemurafenib, dabrafenib Inhibition of BRAF
Ibrutinib Bruton’s tyrosine kinase inhibitor
Trematinib, selumetinib MAPK (mitogen activated protein kinase) inhibitors
Moxetumomab pasudotox High-affinity anti-CD22 immunotoxin